Eli Lilly (NYSE:LLY) “Overweight” Rating Reaffirmed Today By Barclays; The Target Price Given is $107

September 8, 2018 - By Margaret Guttierez

Eli Lilly and Company (NYSE:LLY) Logo

Investors sentiment decreased to 0.78 in Q1 2018. Its down 0.32, from 1.1 in 2017Q4. It worsened, as 76 investors sold Eli Lilly and Company shares while 427 reduced holdings. 82 funds opened positions while 308 raised stakes. 810.94 million shares or 1.95% less from 827.08 million shares in 2017Q4 were reported.

Hsbc Holding Public Ltd reported 2.10 million shares stake. Paradigm Asset Management Co Ltd Liability Corp holds 0% of its portfolio in Eli Lilly and Company (NYSE:LLY) for 29,010 shares. Taurus Asset Management Ltd Liability reported 0.04% stake. 280,354 were reported by Arizona State Retirement. Capital Invest Ltd Liability Corporation accumulated 35,127 shares. Mechanics State Bank Trust Department has invested 0.09% of its portfolio in Eli Lilly and Company (NYSE:LLY). Moreover, Shine Advisory has 0.06% invested in Eli Lilly and Company (NYSE:LLY) for 1,373 shares. Timber Creek Capital Management Ltd Liability Co invested in 59,731 shares or 2.92% of the stock. Moreover, Pictet Asset Mngmt Ltd has 0.19% invested in Eli Lilly and Company (NYSE:LLY) for 995,451 shares. Filament Ltd Liability Corp has invested 0.67% in Eli Lilly and Company (NYSE:LLY). Chicago Equity Prtn Ltd Liability Com has invested 0.04% in Eli Lilly and Company (NYSE:LLY). 5,051 were accumulated by Cape Cod Five Cents Fincl Bank. Deutsche Fincl Bank Ag reported 3.86 million shares. James Invest Research invested 0% of its portfolio in Eli Lilly and Company (NYSE:LLY). Thompson Siegel & Walmsley Lc accumulated 0% or 3,741 shares.

Since March 16, 2018, it had 2 insider purchases, and 24 sales for $254.47 million activity. 22,544 shares were sold by Mahony Susan, worth $1.81M. 2,168 shares valued at $206,437 were bought by TAI JACKSON P on Thursday, July 26. $237,600 worth of Eli Lilly and Company (NYSE:LLY) was sold by Smiley Joshua L on Friday, March 16. $691,775 worth of Eli Lilly and Company (NYSE:LLY) was sold by Shaw Christi on Tuesday, May 29. 25,000 shares valued at $2.13M were sold by Conterno Enrique A on Thursday, May 31. Skovronsky Daniel also bought $862,200 worth of Eli Lilly and Company (NYSE:LLY) shares.

Eli Lilly (NYSE:LLY) Rating Reaffirmed

New York: In an analyst report revealed to investors on 7 September, Barclays restate their “Overweight” rating on Eli Lilly (NYSE:LLY) shares. They now have a $107 target price per share on the company. Barclays’s target gives a potential downside of -0.03 % from the company’s last stock price.

Eli Lilly and Company (NYSE:LLY) Ratings Coverage

Among 11 analysts covering Eli Lilly & Co (NYSE:LLY), 5 have Buy rating, 1 Sell and 5 Hold. Therefore 45% are positive. Eli Lilly & Co has $110 highest and $78 lowest target. $96.67’s average target is -9.68% below currents $107.03 stock price. Eli Lilly & Co had 18 analyst reports since March 23, 2018 according to SRatingsIntel. The company was maintained on Wednesday, April 25 by BMO Capital Markets. As per Friday, June 22, the company rating was downgraded by DZ Bank. Bank of America maintained it with “Neutral” rating and $94 target in Wednesday, July 25 report. The stock of Eli Lilly and Company (NYSE:LLY) has “Hold” rating given on Wednesday, July 25 by Berenberg. BMO Capital Markets maintained the stock with “Market Perform” rating in Thursday, July 19 report. The stock has “Underperform” rating by Credit Suisse on Wednesday, July 25. The stock of Eli Lilly and Company (NYSE:LLY) has “Market Perform” rating given on Friday, April 13 by BMO Capital Markets. Jefferies maintained Eli Lilly and Company (NYSE:LLY) on Friday, April 13 with “Buy” rating. The firm earned “Neutral” rating on Tuesday, July 17 by Bank of America. On Monday, June 11 the stock rating was maintained by J.P. Morgan with “Buy”.

The stock increased 1.58% or $1.66 during the last trading session, reaching $107.03. About 3.82 million shares traded or 9.53% up from the average. Eli Lilly and Company (NYSE:LLY) has risen 5.65% since September 8, 2017 and is uptrending. It has underperformed by 6.92% the S&P500.

Analysts await Eli Lilly and Company (NYSE:LLY) to report earnings on October, 23. They expect $1.35 earnings per share, up 28.57 % or $0.30 from last year’s $1.05 per share. LLY’s profit will be $1.38B for 19.82 P/E if the $1.35 EPS becomes a reality. After $1.50 actual earnings per share reported by Eli Lilly and Company for the previous quarter, Wall Street now forecasts -10.00 % negative EPS growth.

Eli Lilly and Company discovers, develops, makes, and markets pharmaceutical products worldwide. The company has market cap of $109.08 billion. It operates through two divisions, Human Pharmaceutical Products and Animal Health Products. It currently has negative earnings. The firm offers endocrinology products to treat diabetes; osteoporosis in postmenopausal women and men; human growth hormone deficiency and pediatric growth conditions; and testosterone deficiency.

More important recent Eli Lilly and Company (NYSE:LLY) news were published by: Seekingalpha.com which released: “Elanco announces launch of IPO roadshow” on September 06, 2018, also Streetinsider.com published article titled: “Eli Lilly & Co. (LLY), Avid Radiopharmaceuticals Inc. Report Positive Phase 3 Results in Study of Flortaucipir PET …”, Fool.com published: “Better Buy: Pfizer Inc. vs. Eli Lilly and Company” on September 04, 2018. More interesting news about Eli Lilly and Company (NYSE:LLY) was released by: Seekingalpha.com and their article: “Elanco Animal Health Proposes Terms For US IPO” with publication date: September 07, 2018.

Eli Lilly and Company (NYSE:LLY) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.